TAGAMET HB (cimetidine) by Teva is histamine h2 receptor antagonists [moa]. First approved in 1995.
Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TAGAMET HB (cimetidine) is an oral histamine-2 receptor antagonist approved in 1995 for reducing stomach acid production. It is used primarily for heartburn, acid reflux, and peptic ulcer disease in over-the-counter and prescription settings. The drug works by blocking H2 receptors on gastric parietal cells to decrease gastric acid secretion.
Product faces approaching loss of exclusivity with moderate competitive pressure (30), indicating shrinking team size and focus on cost management and generic transition planning.
Histamine H2 Receptor Antagonists
Histamine-2 Receptor Antagonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of Cimetidine on the PK of Imeglimin
Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects
Drug-drug Interaction Study of CHF5993 With Cimetidine
Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body
Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX
Worked on TAGAMET HB at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on TAGAMET HB offers limited growth opportunity as the product approaches or has entered loss of exclusivity with minimal linked job openings. Career value lies in managing mature brand transitions, generic competition, and OTC market retention rather than innovation or expansion.